Filtered By:
Condition: Multiple Sclerosis
Therapy: Corticosteroid Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 24 results found since Jan 2013.
Management and long-term outcomes of patients with chronic inflammatory diseases experiencing ST-segment elevation myocardial infarction: The SCALIM registry
CONCLUSIONS: Approximately 1 in 20 patients with STEMI has CID. We found no effect of CID on long-term survival. However, patients on corticosteroid therapy appeared to have higher rates of death during follow-up. Whether this finding is related to the use of corticosteroids or to the more progressive nature of their condition warrants further investigation.PMID:36372664 | DOI:10.1016/j.acvd.2022.09.003
Source: Archives of Cardiovascular Diseases - November 13, 2022 Category: Cardiology Authors: Marouane Boukhris Nicolas Dupire Benjamin Dousset Val érie Pradel Patrice Virot Julien Magne Victor Aboyans Source Type: research
Levamisole-Induced Leukoencephalopathy in Russia: Analysis of 30 Cases
CONCLUSION: The differential diagnosis remains difficult for suspected cases of LEV-induced MIL that could lead to delayed therapy initiation, and consequently incomplete recovery. Growing evidence suggests that a single administration of levamisole even in low doses might potentially lead to severe neurological deficit or death. Therefore, changes in medication management policies are required in order to prevent uncontrolled use of levamisole.PMID:34951579 | DOI:10.2174/1574886317666211224121517
Source: Current Drug Safety - December 24, 2021 Category: Drugs & Pharmacology Authors: Zakharova Maria Nikolaevna Zakroyshchikova Inessa Vladimirovna Kozlova Alexandra Olegovna Zabirova Alfiia Hodzhaevna Askarova Lola Shavkatovna Zhirova Ekaterina Stanislavovna Source Type: research
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Balo's Concentric Sclerosis with monophasic course: A report of 2 cases
CONCLUSION: BCS appears to have a good prognosis when treated early in its diagnosis with steroids.PMID:34401123 | PMC:PMC8347801 | DOI:10.1016/j.amsu.2021.102602
Source: Annals of Medicine - August 17, 2021 Category: Internal Medicine Authors: Hector R Martinez Irving Christian Rodriguez-Gonzalez Juan M Escamilla-Garza Jose A Figueroa-Sanchez Axel Cruz Garcia-Aleman David Eugenio Hinojosa-Gonzalez Source Type: research
